科研 - 新產品及分析技術開發


  • 我們不斷開發新的遺傳分析技術及其臨床應用. Rainbow Genomics constantly develops new genetic analysis technologies and their clinical applications

  • 通過與我們合作的臨床醫學夥伴及其科學平台,我們開發了以下新的產品和遺傳分析技術. By working with our clinical partners and their platforms, we developed the following new products and genetic analysis technologies


“小兒1000”檢測研發

Healthy Pediatric Exome Screening Test Product Development

  • Rainbow “小兒1000”檢測 - 是依據美國哈佛大學醫學院和波士頓兒童醫院實施的BabySeq兒科基因篩查計劃為藍本。

  • 我們除了引進了這種新的基因檢測策略我們還與Fabric Genomics共同開發了大約200個額外的基因組。該基因組包括針對兒科疾病的最新基因註釋(文獻發表於2018)。我們的“小兒1000”檢測現在已經包含了1700個,與1000多種兒科疾病相關的基因

  • 目前亞洲尚無此類基因篩查檢測

  • For the Healthy Pediatric Exome Screening Test, which is based on the BabySeq project implemented at the Boston Children’s Hospital and Harvard Medical School, we co-developed an additional gene panel of approximately 200 genes with Fabric Genomics and clinicians in Asia.

  • The panel includes the latest genes annotated (2018) for childhood-onset disorders. Our total interpretation menu now includes 1700 genes associated with over 1000 childhood-onset genetic disorders.


用於全外顯子組的心臟基因分析研發

Cardio Panel for Focused Heart Disease Analysis Coupled with UCLA Whole Exome Clinical Interpretation

  • 與洛杉磯加州大學臨床基因組學中心的團隊合作,Rainbow共同開發了一個有100多個基因的基因組,針對單基因心血管疾病和肌肉萎縮症

  • 通過訂購"成人兒科全外顯子組檢測“,醫生可以另外訂購這個心臟基因組分析(不額外收費)。這個有助於UCLA的醫學團隊能夠解釋患者症狀的同時,也關註一系列心血管疾病基因變異

  • By working with the team at UCLA’s Clinical Genomic Center, Rainbow co-developed a cardio panel with over 100 genes that target monogenic cardiovascular diseases and muscular dystrophy disorders.

  • This panel is now available for order with the UCLA adult and pediatric whole exome sequencing test, enabling their medical team to focus on a range of cardiovascular disorders while interpreting patient’s other symptoms.


用於全外顯子組的癌症基因分析研發

並加入了常見癌症的風險評估以降低患病風險

Cancer Gene Panel for Comprehensive Cancer Screening Coupled with Baylor’s Exome Clinical Interpretation

Integrated Common Cancer Risk Assessment to Motivate Improved Liefstyle

  • 與Baylor Genetics的臨床醫學團隊合作,Rainbow共同開發了100多種基因,用於篩選大多數已知的遺傳性癌症的基因變異。這是對沒有症狀或家族史的個人的最全面的癌症篩查檢測。

    我們也採用SNP標記對7種常見癌症進行風險評估。

  • 癌症60種檢測 - 我們率先使用遺傳性癌症風險(與非基因變異攜帶者相比,風險高5-20倍)和普通癌症風險(與非基因變異攜帶者相比,風險高1.3-3倍)。結合的報告可以激勵患者改善個人生活方式。改善生活方式和飲食習慣可以幫助降低整體癌症風險。

    目前亞洲尚無此類攜帶“臨床應用性”的癌症基因篩查檢測

  • Working with Baylor Genetics’ clinical team, Rainbow co-developed over 100 genes for screening of most known hereditary cancer gene variants. This is the most comprehensive cancer screening test available to individuals without symptoms or family history.

  • Rainbow also adopts the use of SNP (Single Nucleotide Polymorphism) markers for risk assessment of seven common cancers. We are among the first to provide both hereditary cancer risk (5-20 times higher risk compared to non-carriers) and common cancer risk (1.3-3 times higher risk compared to non-carriers) to motivate individuals to improve their life style/follow screening guidelines.